NCT00412737 - A Study of Oseltamivir (Tamiflu) for the Seasonal Prophylaxis of Influenza in Immunocompromised Participants | Biotech Hunter

Enrollment

477

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions

Influenza

Interventions

DRUG

Oseltamivir

Oseltamivir 30 mg to 75 mg capsule or suspension orally once daily for 12 weeks.

DRUG

Placebo

Placebo matched to oseltamivir capsule or suspension orally once daily for 12 weeks.

Trial Locations (78)

1090

Brussels

1097

Budapest

1200

Brussels

2650

Edegem

3000

Leuven

6720

Szeged

7624

Pécs

9300

Aalst

10023

New York

10032

New York

10098

Berlin

10617

Tallinn

14263

Buffalo

15213

Pittsburgh

17033

Hershey

19104

Philadelphia

19718

Newark

20251

Hamburg

27100

Pavia

27705

Durham

28006

Madrid

28040

Madrid

28207

Charlotte

30309

Atlanta

30912

Augusta

31054

Toulouse

33701

St. Petersburg

35128

Padua

35233

Birmingham

37044

Tours

44195

Cleveland

45267

Cincinnati

48201

Detroit

49100

Petah Tikva

50009

Kaunas

51014

Tartu

52057

Aachen

52621

Ramat Gan

55430

Brooklyn Center

59802

Missoula

60611

Chicago

60612

Chicago

69120

Heidelberg

70121

New Orleans

72202

Little Rock

75019

Paris

75203

Dallas

75475

Paris

75743

Paris

77030

Houston

80262

Denver

80336

München

81675

München

91120

Jerusalem

94305

Stanford

06106-3316

Hartford

48202-2689

Detroit

08103

Camden

07601

Hackensack

07039

Livingston

07112

Newark

27599-7211

Chapel Hill

73112-44A1

Oklahoma City

T6G 2B7

Edmonton

V3K 3P4

Coquitlam

R3E 3P4

Winnipeg

N6A 5A5

London

S7M 0Z9

Saskatoon

639 00

Brno

00168

Roma

08661

Vilnius

15-540

Bialystok

90-153

Lodz

70-111

Szczecin

02-006

Warsaw

04-730

Warsaw

B15 2TH

Birmingham

EH16 4SA

Edinburgh

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY